Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in moderate to severe atopic dermatitis
NCT03496974Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bermekimab in atopic dermatitis (AD), sponsored by Janssen Pharmaceutical. Started May 2018; status: completed.
02
Drugs
bermekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03496974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496974.